What was Regeneron's primary revenue driver during this period?

Regeneron's primary revenue driver was EYLEA (aflibercept) Injection. Net product sales in the U.S. for EYLEA saw a significant increase, contributing substantially to the company's overall revenue growth.

How did the company's collaboration revenues perform?

Collaboration revenues from both Sanofi and Bayer HealthCare showed strong growth. Sanofi collaboration revenue increased significantly due to reimbursement for R&D expenses related to antibody collaborations, while Bayer HealthCare collaboration revenue also saw substantial growth driven by EYLEA profits and sales milestones outside the U.S.

What is the impact of increased R&D spending on the company's profitability?

The company significantly increased its R&D spending, particularly in clinical trial expenses and cost-sharing with collaborators. While this investment is crucial for pipeline development, it led to a decrease in net income for the first half of 2014 compared to the prior year, despite revenue growth.

How did the company's cash position evolve?

Regeneron's cash and cash equivalents, along with marketable securities, increased significantly, reaching $1.37 billion by the end of the period. This strong liquidity position was supported by operating activities and provides a solid foundation for continued investment in research, development, and commercialization.

REGN 10-Q Quarterly Report Q2 FY2014 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported strong revenue growth for the second quarter and first half of 2014, driven primarily by robust sales of EYLEA. Total revenues reached $665.7 million for the quarter and $1.29 billion for the first half, representing significant increases year-over-year. Net income was $92.7 million in Q2 2014, up from $87.4 million in Q2 2013, though net income for the first half of 2014 decreased to $158.2 million from $186.3 million in the prior year, impacted by higher research and development expenses and a significant increase in income tax expense. The company also saw increased collaboration revenue from both Sanofi and Bayer HealthCare, highlighting the progress in its key partnerships. The company's pipeline continues to advance, with notable progress in late-stage antibody programs like alirocumab and dupilumab. EYLEA received FDA approval for diabetic macular edema (DME) in July 2014, further expanding its market potential. Significant investments in research and development were made, particularly in clinical trials for key antibody candidates. Financially, Regeneron maintained a strong cash position, ending the period with over $1.36 billion in cash and marketable securities.

Financial Highlights

47 data points

Beta

Revenue

$665.70M

1.0% Gross Margin

Net Income

$96.35M

0.1% Net Margin

EPS (Diluted)

$0.85

Total Assets

$3.46B

Cash & Equivalents

$600.13M

Free Cash Flow

$336.41M

Financial Statements

Beta

Revenue	$665.70M
Cost of Revenue	$29.95M
Gross Profit	$635.75M
R&D Expenses	$294.50M
SG&A Expenses	$96.73M
Operating Expenses	$437.61M
Operating Income	$228.09M
Interest Expense	$10.18M
Net Income	$96.35M
EPS (Basic)	$0.96
EPS (Diluted)	$0.85
Shares Outstanding (Basic)	100.39M
Shares Outstanding (Diluted)	113.03M

Key Highlights

1Total revenues increased by 45% year-over-year to $665.7 million in Q2 2014 and by 44% for the first half of 2014 to $1.29 billion.
2EYLEA net product sales in the U.S. grew to $414.8 million in Q2 2014, up from $329.8 million in Q2 2013, indicating strong market adoption.
3Collaboration revenue from Sanofi and Bayer HealthCare more than doubled year-over-year for both the quarter and the first half, reflecting strong partnership performance.
4Research and development expenses significantly increased by 57% in Q2 2014 to $294.5 million, driven by expanded clinical trial activities and cost-sharing obligations.
5Net income for Q2 2014 was $92.7 million, a modest increase from $87.4 million in Q2 2013, but net income for the first half decreased due to higher R&D spend and increased tax expenses.
6The company ended the period with a healthy cash and marketable securities balance of $1.37 billion, providing ample resources for ongoing operations and development.
7EYLEA received FDA approval for diabetic macular edema (DME) in July 2014, expanding its approved indications.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2014

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions